The right not to know: an autonomy based approach
暂无分享,去创建一个
[1] S. Greene,et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus , 1997, The Lancet.
[2] Johannes J. M. van Delden,et al. Reflective Equilibrium as a Normative-Empirical Model in Bioethics , 1998 .
[3] C. Pedersen,et al. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. , 1999, Clinical therapeutics.
[4] P. Tugwell,et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. , 2000, Rheumatology.
[5] P. Giral,et al. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. , 1999, Journal of clinical epidemiology.
[6] M. Gibbons. Choice and Responsibility: Innovation in a New Context , 2005 .
[7] J. Fletcher,et al. Privacy and disclosure in medical genetics examined in an ethics of care. , 1991, Bioethics.
[8] J. Donovan,et al. Patient Decision Making: The Missing Ingredient in Compliance Research , 1995, International Journal of Technology Assessment in Health Care.
[9] H. Ten Have,et al. Geneticization: the Cyprus paradigm. , 1998, The Journal of medicine and philosophy.
[10] M. Flaten,et al. Drug-related information generates placebo and nocebo responses that modify the drug response. , 1999, Psychosomatic medicine.
[11] R. A. Sears. THE RIGHT NOT TO KNOW. , 1965, South Dakota journal of medicine.
[12] L. Doyal. Closing the gap between professional teaching and practice , 2001, BMJ : British Medical Journal.
[13] G. Hottois. A philosophical and critical analysis of the European convention of bioethics. , 2000, The Journal of medicine and philosophy.
[14] J L Bootman,et al. Drug-related morbidity and mortality. A cost-of-illness model. , 1995, Archives of internal medicine.
[15] W. Haefeli,et al. [Conviction as a basis for compliance and strategies for improving compliance]. , 1999, Schweizerische medizinische Wochenschrift.
[16] J. Rawls,et al. A Theory of Justice , 1971, Princeton Readings in Political Thought.
[17] L. Forrow,et al. Deciding for others: The ethics of surrogate decision‐making , 1990 .
[18] J Singer,et al. The consent form as a possible cause of side effects , 1987, Clinical pharmacology and therapeutics.
[19] R. Hayward,et al. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer. , 2001, JAMA.
[20] A. Clarke. The genetic testing of children. , 1995, Journal of medical genetics.
[21] D. Malone,et al. The Relationship between Drug Therapy Noncompliance and Patient Characteristics, Health‐Related Quality of Life, and Health Care Costs , 2000, Pharmacotherapy.
[22] S. Maffettone,et al. Political liberalism , 2004 .
[23] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[24] J. Oakley. Democracy, embryonic stem cell research, and the Roman Catholic church , 2002, Journal of medical ethics.
[25] Stephanie L. Anderson. GENETIC PRIVACY: A CHALLENGE TO MEDICO-LEGAL NORMS , 2004, The Journal of legal medicine.
[26] V. English,et al. Genetic privacy: orthodoxy or oxymoron? , 1999, Journal of medical ethics.
[27] V. K. Bajaj,et al. Background noise in healthy volunteers--a consideration in adverse drug reaction studies. , 1992, Indian journal of physiology and pharmacology.
[28] C. Pope,et al. The ethics of intimate examinations-teaching tomorrow's doctors. , 2003, BMJ : British Medical Journal.
[29] D. Haslett,et al. What is Wrong with Reflective Equilibria , 1987 .
[30] G. Laurie. In defence of ignorance: genetic information and the right not to know. , 1999, European journal of health law.
[31] G. Laurie,et al. Protecting and promoting privacy in an uncertain world: further defences of ignorance and the right not to know. , 2000, European journal of health law.
[32] R. Chadwick,et al. Book Reviews-The Right to Know and the Right Not to Know , 1997 .
[33] O. O’neill,et al. Some limits of informed consent , 2003, Journal of medical ethics.
[34] K. Keywood,et al. Ignorance, Information and Autonomy , 2001, Theoretical medicine and bioethics.
[35] N. Col,et al. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. , 1990, Archives of internal medicine.
[36] D A Hussar,et al. Detection methods and strategies for improving medication compliance. , 1991, American journal of hospital pharmacy.
[37] L. Foss. Thirteen Ways of Looking at a Blackbird , 1980 .
[38] M. Tohen,et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. , 1999, The Journal of clinical psychiatry.
[39] Knowledge of the legislation governing proxy consent to treatment and research , 2003, Journal of medical ethics.
[40] G. Gillett,et al. The bioethical structure of a human being. , 2003, Journal of applied philosophy.
[41] P D Cleary,et al. What do patients value in their hospital care? An empirical perspective on autonomy centred bioethics , 2003, Journal of medical ethics.
[42] M. Ibrahim,et al. Medication noncompliance--a thriving problem. , 1999, The Medical journal of Malaysia.
[43] N. Swerdlow,et al. Copernican revolution , 1975, Nature.
[44] M. Bottis. Comment on a view favoring ignorance of genetic information: confidentiality, autonomy, beneficence and the right not to know. , 2000, European journal of health law.
[45] Graeme T. Laurie. CHALLENGING MEDICAL-LEGAL NORMS: THE ROLE OF AUTONOMY, CONFIDENTIALITY, AND PRIVACY IN PROTECTING INDIVIDUAL AND FAMILIAL GROUP RIGHTS IN GENETIC INFORMATION , 2001, The Journal of legal medicine.
[46] L. Skene,et al. The role of the church in developing the law , 2002, Journal of medical ethics.
[47] A. Barsky,et al. Nonspecific medication side effects and the nocebo phenomenon. , 2002, JAMA.
[48] R H Brook,et al. The public release of performance data: what do we expect to gain? A review of the evidence. , 2000, JAMA.